Biosimilars – Forecast – Overview Of Biosimilar Forecasts
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these therapy areas totaled approximately $15 billion. Throughout the 2021-2031 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Overview Of Biosimilar Forecasts
- Overview of biosimilar forecasts
- Key drivers and barriers to biosimilars in the major markets
- Total major-market reference brand and biosimilar market shares: 2031
- Total major-market reference brand and biosimilar market shares
- Biosimilar erosion
- Example of the erosion of biologics' uptake by biosimilar competition
- Biosimilar erosion in the major markets
- Biosimilar erosion in the major markets: 2021, 2026, 2031
- Total major-market reference-brand and biosimilar sales: 2021-2031
- Definitions
- Biosimilar erosion in the major pharmaceutical markets
- Biosimilar and reference-brand sales and total market savings in the major markets: 2021-2031
- Order of biosimilar entry across the major markets
- U.S. sales of reference brands and biosimilars: 2021-2031
- EU5 sales of reference brands and biosimilars: 2021-2031
- Japanese sales of reference brands and biosimilars: 2021-2031
- Major-market sales of reference brands and biosimilars: 2021-2031
- Sales erosion of major-market reference brands: 2021-2031
- Major-market share of biosimilars by region: 2021-2031
- Major-market share of biosimilars by class: 2021-2031
- Overview of biosimilar forecasts
Yashu Malhotra, M.Pharm., is an analyst on the Biosimilars and Oncology teams at Clarivate. Previously, she was a senior analyst in the life sciences department at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.
